Daily pill can double survival time for world’s deadliest cancer, trial shows
A clinical trial has shown that the daily pill daraxonrasib can double survival time for patients with advanced pancreatic cancer. Experts are calling this breakthrough a 'gamechanger' in the treatment of one of the deadliest cancers. The trial results indicate that patients taking daraxonrasib lived an average of 13.2 months, compared to 6.6 to 6.7 months for those receiving chemotherapy.
- ▪The trial involved 500 patients with advanced pancreatic cancer.
- ▪Daraxonrasib has fewer side effects compared to traditional chemotherapy.
- ▪Patients taking daraxonrasib experienced a significant increase in survival time, averaging 13.2 months.
Opening excerpt (first ~120 words) tap to expand
The trial of 500 patients also found daraxonrasib had fewer side effects than chemotherapy. Photograph: Jeff Moore/PAView image in fullscreenThe trial of 500 patients also found daraxonrasib had fewer side effects than chemotherapy. Photograph: Jeff Moore/PAPancreas cancerDaily pill can double survival time for world’s deadliest cancer, trial showsExperts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancerAndrew Gregory Health editor in ChicagoSun 31 May 2026 08.00 EDTLast modified on Sun 31 May 2026 08.01 EDTSharePrefer the Guardian on GoogleA daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in…
Excerpt limited to ~120 words for fair-use compliance. The full article is at the Guardian.
Discussion
0 commentsMore from the Guardian
